NASDAQ:TWST

Twist Bioscience Corporation Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Retrieved on: 
Wednesday, May 8, 2024
Biotechnology, Health, Genetics, Pharmaceutical, Health Technology, Silicon, Vesting, Employment, Graduation

As required by the rules of the Nasdaq Stock Market, Twist Bioscience Corporation (NASDAQ: TWST) (“Twist” or the “Company”), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that it has granted a total of 87,200 restricted stock units (“RSUs”) to 26 recently hired individuals as an inducement material to their acceptance of employment with Twist.

Key Points: 
  • As required by the rules of the Nasdaq Stock Market, Twist Bioscience Corporation (NASDAQ: TWST) (“Twist” or the “Company”), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that it has granted a total of 87,200 restricted stock units (“RSUs”) to 26 recently hired individuals as an inducement material to their acceptance of employment with Twist.
  • The employment inducement awards were granted under Twist’s Inducement Equity Incentive Plan and related form of restricted stock award agreement in accordance with Nasdaq Listing Rule 5635(c)(4).
  • The inducement plan is used exclusively for the grant of equity awards to individuals who were not previously employees of Twist, or following a bona fide period of non-employment, as an inducement material to such individuals entering into employment with Twist, pursuant to Nasdaq Listing Rule 5635(c)(4).
  • The RSUs vest over a 48-month period for each employee as follows: 25% vests on the one year anniversary of the start date of the employee (the “Vesting Commencement Date”), and 1/16 of the RSUs vest on each quarterly anniversary (or the last day of the month if no such day exists) of the Vesting Commencement Date thereafter, subject to the employee’s continued service through each vesting date.

Twist Bioscience Reports Fiscal Second Quarter 2024 Financial Results

Retrieved on: 
Thursday, May 2, 2024
Technology, Biotechnology, Nanotechnology, Chemicals, Plastics, Health, Manufacturing, Pharmaceutical, Other Science, Research, General Health, Genetics, Health Technology, Science, Data Management, Twist, Doctor of Philosophy, Nucleic acid thermodynamics, Net, Genomics, Investment, Exome, Capital, Sequence, PIN, Depreciation, Silicon, Genetic variation, Growth, Twist Bioscience, NGS, Development, Administration, SynBio, Tax, UHT, Adjustment, Telephone, GAAP, Element, Gene, Tobacco

Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today reported financial results and business highlights for the second quarter of fiscal 2024 ended March 31, 2024.

Key Points: 
  • Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today reported financial results and business highlights for the second quarter of fiscal 2024 ended March 31, 2024.
  • Shipped products to 2,253 customers in the second quarter of fiscal 2024, compared to approximately 2,100 customers in the second quarter of fiscal 2023.
  • Shipped approximately 193,000 genes during the second quarter of fiscal 2024, compared with approximately 152,000 genes during the second quarter of fiscal 2023.
  • For the third quarter of fiscal year 2024, Twist provided the following financial guidance:
    For the fourth quarter of fiscal year 2024, Twist provided the following financial guidance:
    1For in vitro diagnostic use.

Twist Bioscience to Report Fiscal 2024 Second Quarter Financial Results on Thursday, May 2, 2024

Retrieved on: 
Thursday, April 18, 2024
Technology, Research, Genetics, Nanotechnology, Biotechnology, Health, Pharmaceutical, Other Science, Science, Silicon, Telephone, PIN

Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that it will issue its financial results for the fiscal 2024 second quarter ended March 31, 2024, after market close on Thursday, May 2, 2024.

Key Points: 
  • Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that it will issue its financial results for the fiscal 2024 second quarter ended March 31, 2024, after market close on Thursday, May 2, 2024.
  • The company plans to hold a conference call and live audio webcast for analysts and investors at 4:30 p.m. Eastern Time to discuss its financial results and provide an update on the company’s business.
  • The press release with the financial results will be accessible from the company’s website prior to the conference call through the Investor Relations section under the “Company” tab at www.twistbioscience.com .
  • Those parties interested in participating via telephone must register on the Company’s Investor Relations website or by clicking here .

Twist Bioscience Launches Pangenome Spike-in Exome Panel to Enable Advancement of Research for Diverse Populations

Retrieved on: 
Thursday, March 28, 2024
Research, Technology, Semiconductor, Genetics, Nanotechnology, Biotechnology, Hardware, Health, Data Management, Science, Genetic variation, Panel, NHGRI, Twist Bioscience, Twist, WES, Genome, Doctor of Philosophy, Sequence, Production, Exome, Silicon

In order to advance science for all people, researchers need to have tools that enable them to conduct research relevant to people from diverse backgrounds,” said Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience.

Key Points: 
  • In order to advance science for all people, researchers need to have tools that enable them to conduct research relevant to people from diverse backgrounds,” said Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience.
  • “When companies such as Twist utilize our reference standard to create research tools, it facilitates scientists’ study of genetic variation.
  • The Twist Human Pangenome Spike-in Panel targets 2.5 Mb of pangenome variants and can be spiked into the Twist Exome 2.0 to target more than 94% of the novel pangenome variants affecting coding sequences in the exome.
  • If interested in the Human Pangenome Spike-in Panel for the Twist Exome 2.0 panel, please complete the contact form here: https://www.twistbioscience.com/contact

Twist Bioscience Launches IVDR-compliant Precision Dx Products for Whole Exome Sequencing

Retrieved on: 
Tuesday, March 5, 2024
Research, Other Health, Pharmaceutical, Technology, Medical Devices, Genetics, Health Technology, Science, Nanotechnology, Biotechnology, Medical Supplies, Health, Other Science, Twist Bioscience, Twist, Reagent, Silicon, IVDR, NGS, Documentation, Doctor of Philosophy, Safety, Certification, Exon, Genome, Laboratory, DNA, IVD, Workflow, Medical device

The suite of our CE-marked Products includes:

Key Points: 
  • The suite of our CE-marked Products includes:
    The Twist Precision Prep and Enrichment Dx Kit1 (Reagents for enzymatic fragmentation, library preparation, and target enrichment), which is panel-agnostic2
    Twist Precision Exome Dx Kit1 (Reagents for enzymatic fragmentation, library preparation, and target enrichment along with targeted capture probes for exome enrichment; IVDR compliant workflow)
    The Twist Precision Prep and Enrichment Dx Kit and the Twist Precision Exome Dx Panel can be used individually within existing workflows or as a combined solution known as the Twist Precision Exome Dx Kit.
  • “The Twist Precision Dx products are our first NGS product line specifically developed to be included within regulated customer products.
  • The Twist Precision Exome Dx Panel1 is a qualified Twist DNA panel that can be used in conjunction with the Twist Precision Prep and Enrichment Dx kit to produce exome-enriched libraries compatible for NGS applications.
  • Twist Precision Exome Dx Kit1 utilizes the qualified Twist Precision Exome Dx Panel along with the Twist Precision Prep and Enrichment Dx Kit to produce exome-enriched libraries compatible for NGS applications.

Twist Bioscience to Present at Upcoming Investor Conferences

Retrieved on: 
Thursday, February 22, 2024
Technology, Research, Genetics, Nanotechnology, Health Technology, Biotechnology, Health, Pharmaceutical, Science, CFO, Doctor of Philosophy, Barclays, Silicon, Conference, Cryptocurrency

Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that its executives will participate in fireside chats at the following upcoming investor conferences:

Key Points: 
  • Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that its executives will participate in fireside chats at the following upcoming investor conferences:
    Patrick Finn, Ph.D., president and COO, and Adam Laponis, CFO, will participate in a fireside chat at the TD Cowen 44th Annual Health Care Conference on Tuesday, March 5 in Boston, MA; fireside chat at 11:10 a.m. Eastern Time.
  • Emily Leproust, Ph.D., CEO and co-founder, and Adam Laponis, CFO, will participate in a fireside chat at the Barclays 26th Annual Global Healthcare Conference on Tuesday, March 12 in Miami, FL; fireside chat at 7:30 a.m. Eastern Time.
  • The fireside chats will be webcast live and can be accessed by visiting the “Investor Calendar” page of the investor relations section of the company's website here .
  • A replay of the fireside chats will be archived for a period of 30 days following the conclusion of the live events.

Twist Bioscience Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Retrieved on: 
Wednesday, February 7, 2024
Biotechnology, Technology, Health, General Health, Pharmaceutical, Oncology, Other Science, Research, Nanotechnology, Genetics, Science, Silicon, Graduation, Employment, Vesting

As required by the rules of the Nasdaq Stock Market, Twist Bioscience Corporation (NASDAQ: TWST) (“Twist” or the “Company”), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that it has granted a total of 122,400 restricted stock units (“RSUs”) to 36 recently hired individuals as an inducement material to their acceptance of employment with Twist.

Key Points: 
  • As required by the rules of the Nasdaq Stock Market, Twist Bioscience Corporation (NASDAQ: TWST) (“Twist” or the “Company”), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that it has granted a total of 122,400 restricted stock units (“RSUs”) to 36 recently hired individuals as an inducement material to their acceptance of employment with Twist.
  • The employment inducement awards were granted under Twist’s Inducement Equity Incentive Plan and related form of restricted stock award agreement in accordance with Nasdaq Listing Rule 5635(c)(4).
  • The inducement plan is used exclusively for the grant of equity awards to individuals who were not previously employees of Twist, or following a bona fide period of non-employment, as an inducement material to such individuals entering into employment with Twist, pursuant to Nasdaq Listing Rule 5635(c)(4).
  • The RSUs vest over a 48-month period for each employee as follows: 25% vests on the one year anniversary of the start date of the employee (the “Vesting Commencement Date”), and 1/16 of the RSUs vest on each quarterly anniversary (or the last day of the month if no such day exists) of the Vesting Commencement Date thereafter, subject to the employee’s continued service through each vesting date.

Twist Bioscience Launches cfDNA Library Preparation Kit for Liquid Biopsy Applications

Retrieved on: 
Tuesday, February 6, 2024
Science, Other Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Genetics, Whole genome sequencing, Liquid biopsy, Twist Bioscience, Workflow, DNA, Circulating tumor DNA, Patient, Doctor of Philosophy, Disease, Silicon, Neoplasm, NGS, Twist, WGS, Cancer, MRD, Nucleic acid thermodynamics

The Twist cfDNA Library Preparation Kit was purpose-built to maximize the number of unique cfDNA molecules that are captured in library preparation, for higher confidence in the accuracy and sensitivity of liquid biopsy tests.

Key Points: 
  • The Twist cfDNA Library Preparation Kit was purpose-built to maximize the number of unique cfDNA molecules that are captured in library preparation, for higher confidence in the accuracy and sensitivity of liquid biopsy tests.
  • With exceptional accuracy and sensitivity enabled by high conversion rates, the Twist cfDNA Library Preparation Kit can help push the limit of detection and detect lower frequency variants that can be missed by other on market library preparation solutions.”
    The Twist cfDNA Library Preparation Kit adds to Twist’s growing portfolio of tools to support the research and development of liquid biopsy assays, which also includes the recently launched Twist cfDNA Pan-Cancer Reference Standard v2 .
  • The Twist cfDNA Library Preparation Kit can address challenges associated with library preparation from circulating cfDNA with reliable and robust performance from as little as 1ng sample input.
  • The Twist cfDNA Library Preparation Kits are available in two configurations: the cfDNA Library Preparation Kit for whole genome sequencing (WGS) workflows and the Twist Library Preparation and Hyb Mix Kit for target enrichment.

Twist Bioscience and Element Biosciences Collaborate on Exome Sequencing Solutions for AVITI System

Retrieved on: 
Tuesday, February 6, 2024
Research, General Health, Biometrics, Technology, Genetics, Health Technology, Public Relations, Investor Relations, Science, Nanotechnology, Biotechnology, Communications, Health, Other Science, Multimedia, Twist Bioscience, Workflow, Doctor of Philosophy, Exome, Learning, Silicon, NGS, Element, Fine chemical

Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, and Element Biosciences, Inc. , developer of pioneering technologies to empower science, today announced a collaboration to develop the Twist for Element, Exome 2.0 plus Comprehensive Exome Spike-in Workflow for Element’s AVITI™ System.

Key Points: 
  • Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, and Element Biosciences, Inc. , developer of pioneering technologies to empower science, today announced a collaboration to develop the Twist for Element, Exome 2.0 plus Comprehensive Exome Spike-in Workflow for Element’s AVITI™ System.
  • View the full release here: https://www.businesswire.com/news/home/20240206284355/en/
    “Element continues to expand its customer base, bringing high quality and cost-effective sequencing to researchers globally.
  • Pairing Twist’s robust NGS workflows with Element’s AVITI technology will offer customers an economical and streamlined approach to next generation sequencing,” said Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience.
  • If interested in learning more about the Twist for Element, Exome 2.0 plus Comprehensive Exome Spike-in Workflow, please reach out here .

Twist Bioscience Unveils Differentiated Ultra High-Throughput Library Preparation Solution at AGBT

Retrieved on: 
Monday, February 5, 2024
Health, Technology, Genetics, Agritech, Research, Science, Biotechnology, Whole genome sequencing, Twist Bioscience, Workflow, Library, NBL, UHT, Kit, Chemistry, Automation, Doctor of Philosophy, UDI, Genomics, Silicon, NGS, Twist, Breeding, WGS, Fine chemical

Built upon enzymatic fragmentation library preparation, the Twist Flex Prep UHT Kit utilizes novel chemistry that accepts and self-normalizes a wide range of sample input amounts through a new proprietary Normalization By Ligation (NBL) technology.

Key Points: 
  • Built upon enzymatic fragmentation library preparation, the Twist Flex Prep UHT Kit utilizes novel chemistry that accepts and self-normalizes a wide range of sample input amounts through a new proprietary Normalization By Ligation (NBL) technology.
  • The enhanced multiplexing further limits hands on time and saves researchers costs of reagents in downstream purification and indexing steps.
  • Twist will highlight its NGS tools in posters and presentations at the AGBT General Meeting taking place in Orlando, FL February 5-8, 2024.
  • Details are as follows:
    Poster: Twist Pan-Cancer Reference Standards V2: Enhanced Precision and Reduced Errors in ctDNA Analysis